Replicel Life Sciences Stock Performance
| REPCF Stock | USD 0.0001 0.00 0.00% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and RepliCel Life are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days RepliCel Life Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental indicators, RepliCel Life is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
RepliCel |
RepliCel Life Relative Risk vs. Return Landscape
If you would invest 0.01 in RepliCel Life Sciences on November 1, 2025 and sell it today you would earn a total of 0.00 from holding RepliCel Life Sciences or generate 0.0% return on investment over 90 days. RepliCel Life Sciences is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than RepliCel, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
RepliCel Life Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of RepliCel Life for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for RepliCel Life Sciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| RepliCel Life generated a negative expected return over the last 90 days | |
| RepliCel Life has some characteristics of a very speculative penny stock | |
| RepliCel Life Sciences has accumulated 34.26 K in total debt. RepliCel Life Sciences has a current ratio of 0.23, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist RepliCel Life until it has trouble settling it off, either with new capital or with free cash flow. So, RepliCel Life's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like RepliCel Life Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RepliCel to invest in growth at high rates of return. When we think about RepliCel Life's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 353.74 K. Net Loss for the year was (4.07 M) with profit before overhead, payroll, taxes, and interest of 353.74 K. | |
| RepliCel Life Sciences has accumulated about 228 K in cash with (2.51 M) of positive cash flow from operations. | |
| Roughly 68.0% of the company outstanding shares are owned by corporate insiders |
RepliCel Life Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of RepliCel Pink Sheet often depends not only on the future outlook of the current and potential RepliCel Life's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. RepliCel Life's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 27 M | |
| Cash And Short Term Investments | 238.4 K |
RepliCel Life Fundamentals Growth
RepliCel Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of RepliCel Life, and RepliCel Life fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RepliCel Pink Sheet performance.
| Return On Asset | -1.65 | |||
| Operating Margin | (4.19) % | |||
| Current Valuation | 3.42 M | |||
| Shares Outstanding | 54.36 M | |||
| Price To Earning | (1.00) X | |||
| Price To Sales | 8.35 X | |||
| Revenue | 353.74 K | |||
| EBITDA | (4.07 M) | |||
| Cash And Equivalents | 228 K | |||
| Total Debt | 34.26 K | |||
| Book Value Per Share | (0.22) X | |||
| Cash Flow From Operations | (2.51 M) | |||
| Earnings Per Share | (0.09) X | |||
| Total Asset | 591.79 K | |||
| Retained Earnings | (14.76 M) | |||
About RepliCel Life Performance
By analyzing RepliCel Life's fundamental ratios, stakeholders can gain valuable insights into RepliCel Life's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if RepliCel Life has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if RepliCel Life has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada. Replicel Life operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about RepliCel Life Sciences performance evaluation
Checking the ongoing alerts about RepliCel Life for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for RepliCel Life Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| RepliCel Life generated a negative expected return over the last 90 days | |
| RepliCel Life has some characteristics of a very speculative penny stock | |
| RepliCel Life Sciences has accumulated 34.26 K in total debt. RepliCel Life Sciences has a current ratio of 0.23, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist RepliCel Life until it has trouble settling it off, either with new capital or with free cash flow. So, RepliCel Life's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like RepliCel Life Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RepliCel to invest in growth at high rates of return. When we think about RepliCel Life's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 353.74 K. Net Loss for the year was (4.07 M) with profit before overhead, payroll, taxes, and interest of 353.74 K. | |
| RepliCel Life Sciences has accumulated about 228 K in cash with (2.51 M) of positive cash flow from operations. | |
| Roughly 68.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing RepliCel Life's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether RepliCel Life's stock is overvalued or undervalued compared to its peers.
- Examining RepliCel Life's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating RepliCel Life's management team can have a significant impact on its success or failure. Reviewing the track record and experience of RepliCel Life's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of RepliCel Life's pink sheet. These opinions can provide insight into RepliCel Life's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for RepliCel Pink Sheet analysis
When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |